SCYNEXIS Stock

SCYNEXIS Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of SCYNEXIS (SCYX) as of Aug 5, 2026 is 112.78 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 89.73 % — a change of 25.68% (higher).

Cash Conversion

112.78 %

YoY

25.68%

Last updated:

Cash Conversion Rate (OCF/Net Income) of SCYNEXIS is 2026 112.78 % . Cash Conversion Rate (OCF/Net Income) of SCYNEXIS was 2025 89.73 % . It decreases by 25.68% higher compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

Cash Conversion Rate (OCF/Net Income) of SCYNEXIS is 112.78 % in 2026.

Cash Conversion Rate (OCF/Net Income) of SCYNEXIS changed from 89.73 % to 112.78 %, representing a 25.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — SCYNEXIS

All Key Metrics — SCYNEXIS